Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 54.84

+0.2%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (33263)	12/30/2009 2:33:41 PM
From: Pseudo Biologist	1 Recommendation Read Replies (1) of 52153

Apparently the antibody has been around for 1/4 of a century now: ncbi.nlm.nih.gov Clin Immunol Immunopathol. 1984 Nov;33(2):268-81. [One] hybridoma, designated F77-129, was extensively purified and used to characterize a PC-3 antigen. One wonders what motivated them to look back at "the freezer" after all these years. For a number of reasons (glycolipid target, antibody tested is a mouse IgG3, etc) "grain of salt" is right. The naked antibody works impressively as monotherapy in a couple of xenograft prostate cancer mouse models, so, yes, it is worth exploring. Greene likes to claim some credit, I guess deserved to some degree, on the HER2 (Herceptin) story, FWIW. ncbi.nlm.nih.gov (p185 is an older name for HER2) PB

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next